Biomarker testing is an essential part of the precision medicine toolbox that clinicians can use to advance care and make targeted treatment decisions. However, approaches to biomarker testing within and across an organization can vary and lead to inefficient processes, differences in quality of care, and unnecessary costs.
This diagnostic tool is designed to help oncology service line leaders and clinicians understand whether their biomarker testing program is basic, intermediate, or advanced. After using this tool, leaders will be able to identify necessary steps to standardize and improve their organization’s biomarker testing process.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
This material is sponsored by Pfizer, an Advisory Board member organization. Representatives of Pfizer helped select the topics and issues addressed. Advisory Board experts wrote the material, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
Never miss out on the latest innovative health care content tailored to you.